User:Simoncaulton/sandbox
 | |
| Clinical data | |
|---|---|
| Trade names | Phortress |
| Identifiers | |
| |
| PubChem CID | |
| Chemical and physical data | |
| Formula | C20H24ClFN4OS |
| Molar mass | 422.947 g/mol g·mol−1 |
Phortress is a 2-(4-aminophenyl)benzothiazole derivative that is currently in phase-1 clinical trials. It was developed from compound CJM 126, which was previously identified in a kinase inhibitor discovery programme. In order to improve this drug's anti-tumour activity, CJM 126 was derivatised by methylation on its phenolic ring, producing 2-(4-Amino-3-methylphenyl)benzothiazole (DF 203). DF 203 suffered from metabolism at higher concentrations, so a fluorine atom was substituted on the benzothiazole group. Finally, to improve its solubility it was conjugated to lysine forming the final drug for clinical assesment.
